CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 280 enrolled
Drug / intervention
botulinum toxin Type Abiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02147561
NCT02147561Phase 4Completed

A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine

Allergan·interventional·Posted May 26, 2014·Updated May 27, 2016

In Brief

A Phase 4 clinical trial evaluating botulinum toxin Type A for Migraine Disorders. Completed, enrolled 280 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of BOTOX® treatment in Korean adults with chronic migraine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 26, 2014
Enrollment StartJul 1, 2014
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 12.1 years ago

Interventions

botulinum toxin Type Abiological

Botulinum toxin Type A injected across specific head and neck muscles on Day 0.